Key result
IV iron improves functional capacity in HF anemia but ESAs offer no mortality benefit.
Why the study?
Anemia in heart failure is common and linked to increased hospital admissions, morbidities, and mortality, yet research on management has been limited and shown conflicting results.
Do iron supplements and erythropoiesis-stimulating agents improve clinical outcomes in patients with heart failure and anemia?
Population
Heart failure patients with anemia
Design
Narrative review
Authors
Loading...
Supports symptomatic benefit from IV iron in anemic HF; leaves open mortality effects and optimal strategies for prospective trials.
Do iron supplements and erythropoiesis-stimulating agents improve clinical outcomes in patients with heart failure and anemia?
This review reinforces that intravenous iron improves symptoms in anemic heart failure patients, whereas erythropoiesis-stimulating agents do not improve clinical outcomes and are not recommended.
Siddiqui et al. (2022) conducted a review in Heart failure with anemia. Iron supplementation and erythropoiesis-stimulating agents was evaluated. Anemia in heart failure is associated with increased morbidity and mortality; intravenous iron improves functional capacity, while erythropoiesis-stimulating agents show no mortality benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: